Unveiling 14 Analyst Insights On Ultragenyx Pharmaceutical
Unveiling 14 Analyst Insights On Ultragenyx Pharmaceutical
揭示14個分析師對ultragenyx pharmaceutical的見解
14 analysts have shared their evaluations of Ultragenyx Pharmaceutical (NASDAQ:RARE) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 5 | 3 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 1 | 0 | 0 |
| 2M Ago | 4 | 3 | 1 | 0 | 0 |
| 3M Ago | 2 | 1 | 1 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $86.79, along with a high estimate of $127.00 and a low estimate of $45.00. Witnessing a positive shift, the current average has risen by 1.76% from the previous average price target of $85.29.
Decoding Analyst Ratings: A Detailed Look
An in-depth analysis of...
登入免費觀看全文
登入/註冊